|
|
|
YTD 2022
|
|
|
Q3 2022
|
|
|
|
|
% Change
|
|
% Change
|
||
|
|
$m
|
Actual
|
CER[1]
|
$m
|
Actual
|
CER
|
- Product Sales
|
|
32,200
|
29
|
35
|
10,590
|
9
|
16
|
- Collaboration Revenue
|
|
944
|
>2x
|
>2x
|
392
|
>3x
|
>3x
|
Total Revenue
|
|
33,144
|
30
|
37
|
10,982
|
11
|
19
|
|
$1.54
|
>4x
|
>4x
|
$1.06
|
n/m
|
n/m
|
|
Core[4] EPS
|
|
$5.28
|
47
|
52
|
$1.67
|
55
|
70
|
|
% Change
|
|
|
Revenue type
|
|
$m
|
Actual
|
CER
|
|
|
Product Sales
|
|
10,590
|
9
|
16
|
|
Strong
Oncology and BioPharmaceuticals sales
$1,734m
from medicines acquired with Alexion
|
Collaboration Revenue
|
|
392
|
>3x
|
>3x
|
|
$160m for Enhertu (Q3 2021: $52m)
$26m for Tezspire (Q3 2021: $nil)
Milestones of $75m for Lynparza, $62m for Nexium and $40m for
tralokinumab
|
Total Revenue
|
|
10,982
|
11
|
19
|
|
|
Disease areas
|
|
$m
|
Actual
|
CER
|
|
|
Oncology
|
|
4,039
|
20
|
27
|
|
Good
performance across key medicines and regions
|
CVRM9
|
|
2,351
|
11
|
18
|
|
Farxiga achieved its third consecutive blockbuster
quarter with $1,103m in revenues
|
R&I
|
|
1,499
|
1
|
5
|
|
Growth
across Breztri and Fasenra offsetting
a decline in Pulmicort of
33% (31% at CER) primarily due to the impact of
VBP[16] implementation and
COVID-19 lockdowns in China
|
V&I[17]
|
|
878
|
(29)
|
(24)
|
|
$180m from Vaxzevria[18] (Q3
2021: $1,050m)
$536m from Evusheld (Q3 2021: $nil)
|
Rare Disease9
|
|
1,741
|
4
|
11
|
|
$518m from Ultomiris which was up 37% (47% at
CER)
|
Other Medicines
|
|
474
|
34
|
50
|
|
Includes a Collaboration Revenue milestone of $62m
for Nexium.
Nexium revenue in Q3 2021
was negatively impacted by a transition in distribution
partners
|
Total Revenue
|
|
10,982
|
11
|
19
|
|
|
Regions inc. Vaxzevria
|
|
$m
|
Actual
|
CER
|
|
|
Emerging Markets
|
|
2,856
|
(10)
|
(4)
|
|
Decline due to lower sales
of Vaxzevria (growth rates
excluding Vaxzevria shown below)
|
- China
|
|
1,541
|
3
|
8
|
|
Q3 2021 was negatively impacted
by Tagrisso inventory
phasing and stock compensation following NRDL[19] changes
|
- Ex-China Emerging Markets
|
|
1,316
|
(21)
|
(15)
|
|
Decline due to lower sales
of Vaxzevria
|
US
|
|
4,650
|
34
|
34
|
|
|
Europe
|
|
2,065
|
8
|
23
|
|
|
Established RoW
|
|
1,412
|
7
|
26
|
|
|
Total Revenue inc.
Vaxzevria
|
|
10,982
|
11
|
19
|
|
|
Regions exc. Vaxzevria
|
|
$m
|
Actual
|
CER
|
|
Contribution of medicines acquired with Alexion
|
Emerging Markets
|
|
2,826
|
13
|
20
|
|
$102m
|
- China
|
|
1,541
|
3
|
8
|
|
|
- Ex-China Emerging Markets
|
|
1,285
|
26
|
37
|
|
$102m
|
US
|
|
4,650
|
34
|
34
|
|
$1,069m
|
Europe
|
|
2,002
|
14
|
30
|
|
$351m
|
Established RoW
|
|
1,325
|
22
|
45
|
|
$212m
|
Total Revenue exc.
Vaxzevria
|
|
10,803
|
23
|
31
|
|
$1,734m
|
|
|
|
|
|
|
|
Metric
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments[20]
|
Total Revenue
|
$10,982m
|
11% Actual 19% CER
|
$10,982m
|
11% Actual 19% CER
|
|
See
Table 1 and the Total Revenue section of this document for further
details
|
Gross Margin[21]
|
72%
|
10pp Actual 11pp CER
|
81%
|
6pp Actual 7pp CER
|
|
+
Addition of Alexion
+
Increasing mix of Oncology sales
‒ Impact
from profit-sharing arrangements(e.g. Lynparza)
‒ Reported
Gross Margin impacted by unwind of Alexion inventory fair value
adjustment
|
R&D Expense
|
$2,458m
|
-32% Actual -28% CER
|
$2,357m
|
10% Actual 16% CER
|
|
+
Addition of Alexion
+
Increased investment in the pipeline following ungating of
additional late-stage trials
Reported
R&D Expense in Q3 2021 included a $1,172m impairment
charge
Core
R&D-to-Total Revenue ratio of 21%(Q3 2021: 22%)
|
SG&A Expense
|
$4,277m
|
5% Actual 9% CER
|
$3,160m
|
10% Actual 16% CER
|
|
+
Addition of Alexion
+ Market development activities for recent
launches, including Evusheld
+
Core SG&A-to-Total Revenue ratio of 29%(Q3 2021:
29%)
|
Other Operating Income[22]
|
$106m
|
>2x Actual >2x CER
|
$107m
|
>2x Actual >3x CER
|
|
Includes
income from royalties and prior transactions
|
Operating Margin
|
11%
|
28pp Actual 30pp CER
|
31%
|
8pp Actual 9pp CER
|
|
See
Gross Margin and Expensescommentary above
|
Net Finance Expense
|
$324m
|
1% Actual 2% CER
|
$254m
|
16% Actual 14% CER
|
|
+
Foreign exchange movements
+
Interest rate increase on floating rate liabilities
Reported
impacted by discount unwind on acquisition-related
liabilities
|
Tax Rate
|
-78%
|
n/m
|
18%
|
-3pp Actual -3pp CER
|
|
18%
Core Tax Rate in the quarter reflected geographical mix of profits
and favourable adjustments to prior year tax liabilities in a
number of major jurisdictions
Reported
affected by a $883m deferred tax credit arising from a legal
entity reorganisation to integrate Alexion
Variations
in the tax rate can be expected to continue quarter to
quarter
|
EPS
|
$1.06
|
n/m
|
$1.67
|
55% Actual 70% CER
|
|
Further
details of differences between Reported and Core are shown in Table
12
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
Regulatory approvals and other regulatory actions
|
Tagrisso
|
NSCLC (adjuvant) (ADAURA)
|
Regulatory approval (JP)
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory approval (US)
|
|
Imfinzi
|
Liver cancer (1st-line) (HIMALAYA)
|
Regulatory approval (US)
|
|
Lynparza
|
gBRCA[23] breast
cancer (adjuvant) (OlympiA)
|
Regulatory approval (EU, JP)
|
|
Lynparza
|
HRD[24]-positive
advanced ovarian cancer (1st-line maint.)
(PAOLA-1)
|
Regulatory approval (CN)
|
|
Enhertu
|
HER2-low breast cancer (3rd-line) (DESTINY-Breast04)
|
Regulatory approval (US)
|
|
Enhertu
|
HER2m[25] NSCLC
(2nd-line+) (DESTINY-Lung02)
|
Regulatory approval (US)
|
|
Calquence
|
Maleate tablet formulation
|
Regulatory approval (US)
|
|
Forxiga
|
CKD[26] (DAPA-CKD)
|
Regulatory approval (CN)
|
|
Tezspire
|
Severe asthma (NAVIGATOR)
|
Regulatory approval (EU, JP)
|
|
Beyfortus
|
RSV (MELODY/MEDLEY)
|
Regulatory approval (EU)
|
|
Evusheld
|
COVID-19 (PROVENT/TACKLE)
|
Regulatory approval (JP)
|
|
Evusheld
|
COVID-19 (TACKLE)
|
Regulatory approval (EU)
|
|
Soliris
|
PNH and aHUS[27]
|
Regulatory approval (CN)
|
|
Ultomiris
|
gMG (CHAMPION-MG)
|
Regulatory approval (EU, JP)
|
|
Koselugo
|
NF1-PN[28] (SPRINT)
|
Regulatory approval (JP)
|
|
Regulatory submissionsor acceptances
|
Lynparza
|
Prostate cancer (1st-line) (PROpel)
|
Priority Review (US)
|
Enhertu
|
HER2-low breast cancer (3rd-line) (DESTINY-Breast04)
|
Regulatory submission (CN)
|
|
Farxiga/Forxiga
|
HFpEF[29] (DELIVER)
|
Regulatory submission (US, EU, JP, CN)
|
|
Ultomiris
|
NMOSD[30] (CHAMPION-NMOSD)
|
Regulatory submission (US, EU, JP)
|
|
Major Phase III data readouts and other developments
|
capivasertib
|
HR+/HER2-neg breast cancer (1st-line)
(CAPItello-291)
|
Primary endpoint met
|
monalizumab
|
Recurrent or metastatic HNSCC[31](2nd-line)
(INTERLINK-1)
|
Efficacy threshold not met
|
|
Fasenra
|
EoE[32] (MESSINA)
|
One of two dual-primary endpoints not met
|
|
Soliris
|
Guillain-Barré syndrome
|
Primary endpoint not met
|
|
danicopan
|
PNH with extravascular haemolysis
|
Primary endpoint met
|
|
|
YTD 2022
|
Q3 2022
|
||||||
|
|
|
|
% Change
|
|
|
% Change
|
||
Product Sales
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
Oncology
|
|
10,885
|
33
|
14
|
20
|
3,797
|
35
|
15
|
22
|
- Tagrisso
|
|
4,102
|
12
|
11
|
16
|
1,398
|
13
|
12
|
20
|
- Imfinzi
|
|
2,031
|
6
|
14
|
19
|
737
|
7
|
19
|
26
|
- Lynparza
|
|
1,949
|
6
|
13
|
19
|
659
|
6
|
12
|
19
|
- Calquence
|
|
1,469
|
4
|
74
|
77
|
566
|
5
|
60
|
63
|
- Enhertu
|
|
52
|
-
|
>5x
|
>5x
|
23
|
-
|
>4x
|
>4x
|
- Orpathys
|
|
34
|
-
|
>3x
|
>3x
|
11
|
-
|
11
|
16
|
- Zoladex
|
|
717
|
2
|
-
|
6
|
240
|
2
|
(4)
|
5
|
- Faslodex
|
|
259
|
1
|
(21)
|
(14)
|
81
|
1
|
(21)
|
(10)
|
- Iressa
|
|
90
|
-
|
(39)
|
(37)
|
27
|
-
|
(35)
|
(31)
|
- Arimidex
|
|
85
|
-
|
(20)
|
(16)
|
24
|
-
|
(28)
|
(23)
|
- Casodex
|
|
63
|
-
|
(48)
|
(45)
|
21
|
-
|
(46)
|
(40)
|
-
Others
|
|
34
|
-
|
(9)
|
(1)
|
10
|
-
|
(18)
|
(10)
|
BioPharmaceuticals:
CVRM9
|
|
6,907
|
21
|
13
|
18
|
2,348
|
21
|
11
|
19
|
- Farxiga
|
|
3,204
|
10
|
49
|
58
|
1,101
|
10
|
38
|
50
|
- Brilinta
|
|
1,013
|
3
|
(10)
|
(7)
|
338
|
3
|
(10)
|
(7)
|
- Lokelma
|
|
208
|
1
|
71
|
80
|
79
|
1
|
59
|
69
|
-
Roxadustat
|
|
148
|
-
|
2
|
4
|
57
|
1
|
4
|
9
|
- Andexxa9
|
|
111
|
-
|
7
|
14
|
41
|
-
|
5
|
17
|
- Crestor
|
|
824
|
2
|
(2)
|
4
|
277
|
3
|
(7)
|
-
|
- Seloken/Toprol-XL
|
|
705
|
2
|
(6)
|
(2)
|
238
|
2
|
2
|
10
|
- Bydureon
|
|
207
|
1
|
(29)
|
(28)
|
66
|
1
|
(30)
|
(29)
|
- Onglyza
|
|
205
|
1
|
(28)
|
(25)
|
66
|
1
|
(21)
|
(17)
|
-
Others
|
|
282
|
1
|
(9)
|
(7)
|
85
|
1
|
(11)
|
(8)
|
BioPharmaceuticals: R&I
|
|
4,318
|
13
|
(3)
|
-
|
1,427
|
13
|
(4)
|
1
|
- Symbicort
|
|
1,919
|
6
|
(6)
|
(2)
|
630
|
6
|
(7)
|
(1)
|
- Fasenra
|
|
1,015
|
3
|
13
|
17
|
353
|
3
|
10
|
15
|
- Breztri
|
|
282
|
1
|
>2x
|
>2x
|
103
|
1
|
>2x
|
>2x
|
- Saphnelo
|
|
69
|
-
|
>10x
|
>10x
|
33
|
-
|
>10x
|
>10x
|
- Pulmicort
|
|
479
|
1
|
(33)
|
(31)
|
145
|
1
|
(33)
|
(31)
|
- Daliresp
|
|
161
|
-
|
(5)
|
(4)
|
52
|
-
|
(4)
|
(3)
|
- Bevespi
|
|
43
|
-
|
11
|
13
|
14
|
-
|
6
|
8
|
- Others
|
|
350
|
1
|
(21)
|
(20)
|
97
|
1
|
(36)
|
(33)
|
BioPharmaceuticals: V&I
|
|
3,607
|
11
|
51
|
59
|
873
|
8
|
(27)
|
(21)
|
- Vaxzevria
|
|
1,713
|
5
|
(20)
|
(16)
|
173
|
2
|
(83)
|
(81)
|
- Evusheld
|
|
1,451
|
4
|
n/m
|
n/m
|
537
|
5
|
n/m
|
n/m
|
- Synagis
|
|
384
|
1
|
>2x
|
>2x
|
104
|
1
|
(15)
|
(1)
|
- FluMist
|
|
59
|
-
|
(22)
|
(13)
|
59
|
1
|
(19)
|
(10)
|
Rare Disease9
|
|
5,236
|
16
|
4
|
10
|
1,741
|
16
|
4
|
11
|
- Soliris9
|
|
2,918
|
9
|
(7)
|
(2)
|
901
|
8
|
(13)
|
(6)
|
- Ultomiris9
|
|
1,371
|
4
|
27
|
35
|
518
|
5
|
37
|
47
|
- Strensiq9
|
|
687
|
2
|
13
|
15
|
237
|
2
|
17
|
20
|
- Koselugo
|
|
149
|
-
|
>2x
|
>2x
|
48
|
-
|
82
|
81
|
- Kanuma9
|
|
111
|
-
|
6
|
11
|
37
|
-
|
1
|
5
|
Other Medicines
|
|
1,247
|
4
|
(4)
|
4
|
404
|
4
|
17
|
30
|
- Nexium
|
|
986
|
3
|
(1)
|
8
|
311
|
3
|
20
|
36
|
-
Others
|
|
261
|
1
|
(12)
|
(10)
|
93
|
1
|
9
|
13
|
Product Sales
|
|
32,200
|
97
|
29
|
35
|
10,590
|
96
|
9
|
16
|
Collaboration Revenue
|
|
944
|
3
|
>2x
|
>2x
|
392
|
4
|
>3x
|
>3x
|
Total Revenue
|
|
33,144
|
100
|
30
|
37
|
10,982
|
100
|
11
|
19
|
|
|
YTD 2022
|
Q3 2022
|
||||||
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
Enhertu:
alliance revenue[33]
|
|
332
|
35
|
>2x
|
>2x
|
159
|
41
|
>3x
|
>3x
|
Tezspire: alliance
revenue
|
|
42
|
4
|
n/m
|
n/m
|
26
|
7
|
n/m
|
n/m
|
Lynparza: regulatory
milestones
|
|
250
|
26
|
n/m
|
n/m
|
75
|
19
|
n/m
|
n/m
|
Tralokinumab: sales milestone
|
|
110
|
12
|
n/m
|
n/m
|
40
|
10
|
n/m
|
n/m
|
Vaxzevria:
royalties
|
|
67
|
7
|
(19)
|
(22)
|
6
|
2
|
(87)
|
(87)
|
Other royalty income
|
|
54
|
6
|
-
|
-
|
18
|
5
|
(4)
|
(3)
|
Other Collaboration Revenue
|
|
89
|
9
|
(4)
|
12
|
68
|
17
|
>10x
|
>10x
|
Total
|
|
944
|
100
|
>2x
|
>2x
|
392
|
100
|
>3x
|
>3x
|
|
|
YTD 2022
|
Q3 2022
|
||||||
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
Oncology
|
|
11,493
|
35
|
19
|
24
|
4,039
|
37
|
20
|
27
|
BioPharmaceuticals9
|
|
15,078
|
45
|
16
|
21
|
4,728
|
43
|
(2)
|
4
|
- CVRM9
|
|
6,927
|
21
|
13
|
19
|
2,351
|
21
|
11
|
18
|
- R&I
|
|
4,478
|
14
|
-
|
4
|
1,499
|
14
|
1
|
5
|
- V&I
|
|
3,673
|
11
|
49
|
56
|
878
|
8
|
(29)
|
(24)
|
Rare Disease9
|
|
5,236
|
16
|
4
|
10
|
1,741
|
16
|
4
|
11
|
Other Medicines
|
|
1,337
|
4
|
(5)
|
3
|
474
|
4
|
34
|
50
|
Total
|
|
33,144
|
100
|
30
|
37
|
10,982
|
100
|
11
|
19
|
|
|
YTD 2022
|
Q3 2022
|
||||||
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
Emerging Markets
|
|
9,013
|
27
|
5
|
8
|
2,856
|
26
|
(10)
|
(4)
|
- China
|
|
4,597
|
14
|
(2)
|
(1)
|
1,541
|
14
|
3
|
8
|
- Ex-China
|
|
4,415
|
13
|
13
|
20
|
1,316
|
12
|
(21)
|
(15)
|
US
|
|
13,132
|
40
|
58
|
58
|
4,650
|
42
|
34
|
34
|
Europe
|
|
6,429
|
19
|
24
|
37
|
2,065
|
19
|
8
|
23
|
Established RoW
|
|
4,570
|
14
|
38
|
55
|
1,412
|
13
|
7
|
26
|
Total
|
|
33,144
|
100
|
30
|
37
|
10,982
|
100
|
11
|
19
|
|
|
YTD 2022
|
Q3 2022
|
||||||
|
|
|
|
% Change
|
|
|
% Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
Emerging Markets
|
|
8,262
|
25
|
10
|
15
|
2,826
|
26
|
13
|
20
|
- China
|
|
4,551
|
14
|
(3)
|
(2)
|
1,541
|
14
|
3
|
8
|
- Ex-China
|
|
3,711
|
11
|
33
|
44
|
1,285
|
12
|
26
|
37
|
US
|
|
13,053
|
39
|
57
|
57
|
4,650
|
42
|
34
|
34
|
Europe
|
|
6,104
|
18
|
37
|
52
|
2,002
|
18
|
14
|
30
|
Established RoW
|
|
3,945
|
12
|
33
|
50
|
1,325
|
12
|
22
|
45
|
Total
|
|
31,364
|
95
|
35
|
42
|
10,803
|
98
|
23
|
31
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
4,102
|
|
1,211
|
1,472
|
777
|
642
|
Actual change
|
|
11%
|
|
20%
|
14%
|
7%
|
(4%)
|
CER change
|
|
16%
|
|
22%
|
14%
|
19%
|
10%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
Increased use of Tagrisso in adjuvant and 1st-line
setting
|
Emerging Markets
|
|
Increased
1st-line use in China and continued growth in other Emerging
Markets
Rising
demand from increased patient access in China continues to offset
the impact of the March 2021 NRDL price reduction
Q3
2022 growth of 29% (35% at CER) benefited from the comparison to Q3
2021, which was negatively impacted by inventory phasing and stock
compensation relating to NRDL changes in March 2021
In
China, COVID-19 related lockdowns continued to have an adverse
impact in Q3, though at a lower level than Q2
|
US
|
|
Increased EGFR[34] testing
rates
Greater
use in 1st-line with longer duration of treatment and increasing
adjuvant penetration, partially offset by lower 2nd-line
use
|
Europe
|
|
Greater
use in 1st-line and adjuvant settings, with longer duration of
treatment, partially offset by lower 2nd-line use
|
Established RoW
|
|
Increased
use in 1st-line setting and launch progress in adjuvant including
Japan
Q3
Total Revenue decline of 12% (growth of 5% at CER) impacted by a
COVID-19 wave in Japan
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
2,031
|
|
224
|
1,102
|
402
|
303
|
Actual change
|
|
14%
|
|
6%
|
20%
|
16%
|
-
|
CER change
|
|
19%
|
|
9%
|
20%
|
29%
|
14%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
Increased use of Imfinzi to treat patients with
ES-SCLC[35]
Recovery
in rates of diagnosis and treatment following the COVID-19
pandemic
Q3 Worldwide Total Revenue growth of 19% (26% at
CER)
|
Emerging Markets
|
|
Growth in ex-China, offset by an
adverse impact in CRT[36] rates
and hospital use of infused oncology medicines due to COVID-19
lockdowns in several major cities in China
|
US
|
|
New
patient starts across Stage III NSCLC and ES-SCLC
A
strong launch in biliary tract cancer after approval by the US FDA
in September based on the TOPAZ-1 Phase III trial
|
Europe
|
|
Increased
market penetration in ES-SCLC, growth in the number of reimbursed
markets, an ongoing recovery in rates of diagnosis and
treatment
|
Established RoW
|
|
New
reimbursements
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
2,199
|
|
358
|
896
|
743
|
202
|
Actual change
|
|
28%
|
|
27%
|
13%
|
63%
|
8%
|
CER change
|
|
33%
|
|
30%
|
13%
|
75%
|
22%
|
Product Sales
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,949
|
|
358
|
896
|
493
|
202
|
Actual change
|
|
13%
|
|
27%
|
13%
|
8%
|
8%
|
CER change
|
|
19%
|
|
30%
|
13%
|
20%
|
22%
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
Lynparza remains the leading medicine in the
PARP[37]-inhibitor
class globally across four tumour types, as measured by total
prescription volume
Total Revenue includes $250m in regulatory
milestones received from MSD and recognised in Europe, in respect
of the approval in the US and EU for the adjuvant treatment of
patients with gBRCAm[38] breast
cancer, based on the data from the OlympiA Phase III
trial
Q3
Product Sales growth of 12% (19% at CER)
|
Emerging Markets
|
|
Increased patient access
following admission to China's NRDL as a 1st-line maintenance
treatment for BRCAm[39] ovarian
cancer patients, with effect from March 2021; also launches in
other markets
|
US
|
|
US launch in early breast cancer following US
FDA[40] approval
in March based on data from the OlympiA Phase III
trial
Growth
in use in breast, ovarian and prostate cancers
|
Europe
|
|
Increasing HRD testing rates and
use in 1st-line HRD-positive ovarian cancer,
increased Lynparza uptake
in BRCAm mCRPC[41] and
gBRCAm HER2-negative advanced breast cancer and the EU launch in
gBRCAm early breast cancer following EMA[42] approval
in August based on data from the OlympiA Phase III
trial
|
Established RoW
|
|
New
product launches and high levels of HRD testing in
Japan
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
387
|
|
51
|
254
|
77
|
4
|
Actual change
|
|
>2x
|
|
>6x
|
>2x
|
>4x
|
>10x
|
CER change
|
|
>2x
|
|
>6x
|
>2x
|
>4x
|
>10x
|
Region
|
|
Drivers and commentary
|
Worldwide
|
|
Excluding Japan, Enhertu global in-market sales recorded by Daiichi
Sankyo Company Limited (Daiichi Sankyo) and AstraZeneca, amounted
to $750m in the year to date (YTD 2021: $293m)
AstraZeneca's
Total Revenue of $387m includes $335m of Collaboration Revenue from
its share of gross profit in territories where Daiichi Sankyo
records product sales and royalties on sales in Japan
Q3
Worldwide Total Revenue growth of >3x
|
Emerging Markets
|
|
Strong
uptake in early launch markets
|
US
|
|
US
in-market sales, recorded by Daiichi Sankyo, amounted to $532m in
the year to date (YTD 2021: $253m)
US
launches in 2nd-line HER2-positive metastatic breast cancer after
US FDA approval in May based on data from the DESTINY-Breast03
Phase III trial; and in 3rd-line+ HER2-low metastatic breast cancer
after US FDA approval in August based on the DESTINY-Breast04 Phase
III trial
|
Europe
|
|
Growth
in 3rd-line+ HER2-positive metastatic breast and launch in 2nd-line
HER2-positive metastatic breast cancer after EMA approval in July
based on data from the DESTINY-Breast03 Phase III
trial
|
Established RoW
|
|
In
Japan, AstraZeneca receives a mid-single-digit percentage royalty
on sales made by Daiichi Sankyo
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,469
|
|
28
|
1,192
|
200
|
49
|
Actual change
|
|
74%
|
|
>2x
|
58%
|
>2x
|
>4x
|
CER change
|
|
77%
|
|
>2x
|
58%
|
>3x
|
>5x
|
Region
|
|
|
Worldwide
|
|
Q3
Worldwide Total Revenue growth of 60% (63% at CER)
|
US
|
|
Increased new patient market share led to a strong
performance, despite continued COVID-19 impacts on
CLL[43] diagnosis
rates
Maleate
tablet formulation launch in August resulted in uptake by patients
taking proton pump inhibitors and demand due to channel inventory
build
|
Europe
|
|
Increased
market share in new patient starts after launches in the
region
|
|
YTD 2022
|
% Change
|
|
|||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
Zoladex
|
|
738
|
1%
|
7%
|
Increased
use in ex-China Emerging Markets, offsetting a price cut in
Japan
|
|
Faslodex
|
|
259
|
(21%)
|
(14%)
|
Generic
competition
|
|
Iressa
|
|
90
|
(39%)
|
(37%)
|
Continued share loss to next
generation TKIs[45]
|
|
Arimidex
|
|
85
|
(20%)
|
(16%)
|
|
|
Casodex
|
|
63
|
(48%)
|
(45%)
|
Ongoing
impact from VBP implementation
|
|
Other Oncology
|
|
34
|
(9%)
|
(1%)
|
|
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
3,208
|
|
1,224
|
748
|
955
|
281
|
Actual change
|
|
49%
|
|
40%
|
48%
|
64%
|
48%
|
CER change
|
|
58%
|
|
46%
|
48%
|
82%
|
64%
|
Region
|
|
|
Worldwide
|
|
Farxiga volume is growing faster than the overall
SGLT2[46] market
in all major regions
Additional
benefit from growth in the overall SGLT2 inhibitor
class
Further HF[47] and
CKD launches and updated treatment guidelines including from
ESC[48] and
AHA[49]/ACC[50]/HFSA[51].
HF and CKD indications now launched in >100
markets
|
Emerging Markets
|
|
Growth
despite generic competition in some markets. Solid growth in
ex-China Emerging Markets, particularly Latin America
In
China, Forxiga's
NRDL status was renewed in the fourth quarter of 2021. Benefit from
uACR[52] and
MRF[53] screening
programs
|
US
|
|
Regulatory approval for HEFrEF[54] in
May 2020, treatment of CKD in May 2021
Both approvals included patients with and without
T2D[55]
Farxiga continued to gain in-class brand share,
driven by HF and CKD launches
|
Europe
|
|
The
beneficial addition of cardiovascular outcomes trial data to the
label, the HFrEF regulatory approval in November 2020, and CKD
regulatory approval in August 2021
Forxiga continued gaining in-class market share in
the period
|
Established RoW
|
|
In
Japan, AstraZeneca sells to collaborator Ono Pharmaceutical Co.,
Ltd, which records in-market sales. Continued volume growth driven
by HF and CKD launches
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,013
|
|
222
|
538
|
215
|
38
|
Actual change
|
|
(10%)
|
|
(13%)
|
(4%)
|
(18%)
|
(20%)
|
CER change
|
|
(7%)
|
|
(11%)
|
(4%)
|
(9%)
|
(16%)
|
Region
|
|
|
Emerging Markets
|
|
Adverse impact from Brilinta's inclusion in China's VBP
programme
Strong
growth in ex-China Emerging Markets
|
US, Europe
|
|
Slower
market recovery of oral antiplatelet therapies following the
pandemic
|
|
YTD 2022
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
||
Crestor
|
|
825
|
(2%)
|
4%
|
Sales
growth at CER driven by Emerging Markets, offset by declines in the
US and Europe
|
||
Seloken
|
|
706
|
(6%)
|
(2%)
|
Emerging Markets sales impacted
by China VBP implementation of Betaloc[56] oral
in H2 2021. Betaloc ZOK VBP
to be implemented in Q4 2022
|
||
Onglyza
|
|
205
|
(28%)
|
(25%)
|
Ongoing
impact from VBP implementation
|
||
Bydureon
|
|
207
|
(29%)
|
(28%)
|
Continued
competitive pressures
|
||
Other CVRM
|
|
282
|
(9%)
|
(7%)
|
|
||
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,919
|
|
476
|
718
|
445
|
280
|
Actual change
|
|
(6%)
|
|
4%
|
(11%)
|
(11%)
|
(3%)
|
CER change
|
|
(2%)
|
|
8%
|
(11%)
|
(1%)
|
3%
|
Region
|
|
|
Worldwide
|
|
Symbicort remains
the global market leader within stable ICS[57]/LABA[58] class
|
Emerging Markets
|
|
Growth
in Emerging Markets driven primarily by market share growth in
China, Latin America and Asia Area
|
US
|
|
Strong
market share performance, consolidating leadership in a declining
ICS/LABA market, offset by pricing pressure
|
Europe
|
|
Resilient
market share in growing ICS/LABA market, offset by pricing
pressure
|
Established RoW
|
|
Double
digit growth in Canada and Australia/New Zealand, driven by market
share gain
Sales
in Japan declined due to generic erosion and the annual mandatory
price reduction in April 2022
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,015
|
|
30
|
649
|
229
|
107
|
Actual change
|
|
13%
|
|
99%
|
17%
|
9%
|
(10%)
|
CER change
|
|
17%
|
|
95%
|
17%
|
21%
|
-
|
Region
|
|
|
Worldwide
|
|
Fasenra continues to be market leader in severe
eosinophilic asthma in major markets, and leading in the IL-5
class
|
Emerging Markets
|
|
Strong
volume growth driven by launch acceleration in Brazil and other
markets
|
US
|
|
Maintained
a strong new-to-brand share in the severe uncontrolled asthma
market
|
Europe
|
|
Market
leader in new-to-brand share of the severe uncontrolled asthma
market
|
Established RoW
|
|
Maintained
market leadership in Japan, partially offset by price erosion and
impact in the dynamic market related to surge in COVID-19
cases
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
282
|
|
71
|
164
|
22
|
25
|
Actual change
|
|
>2x
|
|
76%
|
>2x
|
>5x
|
43%
|
CER change
|
|
>2x
|
|
78%
|
>2x
|
>6x
|
66%
|
Region
|
|
|
Worldwide
|
|
Breztri continued to gain market share within
growing fixed-dose triple class across major
markets
|
Emerging Markets
|
|
In
China, the FDC triple class continued to penetrate the inhaled
maintenance market whose growth has been impacted by
COVID-19
Breztri continued its market share leadership within
the fixed-dose triple class
|
US
|
|
Consistent
new-to-brand and total market share growth within the fixed-dose
triple class
|
Europe
|
|
Sustained
growth across markets as new launches continue to
progress
|
Established RoW
|
|
Strong new-to-brand market share
performance in Japan within COPD[59],
with the market impacted by access restrictions related to
surge in COVID-19 cases
|
|
YTD 2022
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
||
Pulmicort
|
|
479
|
(33%)
|
(31%)
|
Revenue
from Emerging Markets decreased 41% to $339m, impacted by VBP
implementation in China and lower rates of elective surgery and
limited access to nebulisation centres due to COVID-19
lockdowns
|
||
Daliresp
|
|
161
|
(5%)
|
(4%)
|
|
||
Bevespi
|
|
43
|
11%
|
13%
|
|
||
Other R&I
|
|
469
|
3%
|
4%
|
Collaboration
Revenue of $118m (YTD 2021: $12m), including $111m of milestones
relating to tralokinumab (YTD 2021: nil)
Product
Sales of $350m decreased 21% (20% at CER)
|
||
|
|
|
|
|
|
|
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,780
|
|
751
|
79
|
325
|
625
|
Actual change
|
|
(20%)
|
|
(34%)
|
n/m
|
(56%)
|
82%
|
CER change
|
|
(16%)
|
|
(35%)
|
n/m
|
(51%)
|
96%
|
Region
|
|
|
Worldwide
|
|
Revenue in the third quarter decreased by 83% (82%
at CER) due to the conclusion of many of the
initial Vaxzevria contracts
|
Emerging Markets
|
|
$46m
of Collaboration Revenue came from a Chinese sub-licensee producing
vaccines for export
Revenue
in the third quarter decreased by 95% (96% at CER)
|
US
|
|
Purchases
by the US government for donation overseas
No
revenue recorded in the second and third quarters
|
Europe
|
|
Revenue
in the third quarter decreased by 62% (56% at CER) vs Q3
2021
|
Established RoW
|
|
Sales
in Japan, Canada and Australia
Revenue
in the third quarter decreased by 63% (59% at CER)
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,450
|
|
167
|
850
|
198
|
235
|
Actual change
|
|
n/m
|
|
n/m
|
n/m
|
n/m
|
n/m
|
CER change
|
|
n/m
|
|
n/m
|
n/m
|
n/m
|
n/m
|
Region
|
|
|
US
|
|
Evusheld received Emergency Use Authorisation for the
prevention of COVID-19 in December 2021
AstraZeneca
continued to fulfil the US Government's order for 1.7m
units
|
Emerging Markets
|
|
Multiple
government contracts in Central and Eastern Europe, Latin America
and South East Asia
|
Europe
|
|
Approved
in the EU for prevention of COVID-19 in March 2022 and treatment in
September 2022
|
Established RoW
|
|
Approved
in Japan for prevention and treatment of COVID-19 in August
2022
|
|
YTD 2022
|
% Change
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
Synagis
|
|
384
|
>2x
|
>2x
|
Strong
RSV season
Ex-US
rights reverted to AstraZeneca after 30 June 2021, from AbbVie
Inc.
In Q3 2022, Synagis sales decreased by 15% (1%
CER)
|
FluMist
|
|
59
|
(22%)
|
(13%)
|
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
2,918
|
|
218
|
1,688
|
627
|
385
|
Actual change9
|
|
(7%)
|
|
(29%)
|
(3%)
|
(20%)
|
20%
|
CER change9
|
|
(2%)
|
|
(9%)
|
(3%)
|
(10%)
|
34%
|
Region
|
|
|
US
|
|
Performance impacted by successful conversion
to Ultomiris in PNH, aHUS and gMG, partially offset
by Soliris growth in NMOSD
|
Ex-US
|
|
Growth
driven by continued expansion of neurology indications, gMG and
NMOSD, in new markets
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
YTD 2022 $m
|
|
1,371
|
|
34
|
771
|
347
|
219
|
Actual change9
|
|
27%
|
|
>2x
|
23%
|
55%
|
-
|
CER change9
|
|
35%
|
|
>3x
|
23%
|
74%
|
18%
|
Region
|
|
|
Worldwide
|
|
Performance
driven by gMG launch in the US and expansion into new
markets
Quarter-on-quarter variability in revenue growth
can be expected due to Ultomiris every eight week dosing schedule and lower
average annual treatment cost per patient compared
to Soliris
|
US
|
|
Performance driven by successful conversion
from Soliris across PNH, aHUS and gMG with increased
utilisation from complement-naïve patients in
gMG
|
Ex-US
|
|
Rapid
conversion in new launch markets
|
|
YTD 2022
|
% Change
|
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
Strensiq9
|
|
687
|
13%
|
15%
|
Performance
driven by strong patient demand
|
Koselugo
|
|
149
|
>2x
|
>2x
|
Growth
driven by expansion in new markets and tender market order
timing
|
Kanuma9
|
|
111
|
6%
|
11%
|
Continued
demand growth in ex-US markets
|
|
YTD 2022
|
% Change
|
|
||||
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
||
Nexium
|
|
1,063
|
(3%)
|
7%
|
Collaboration
Revenue of $78m (YTD 2021: $92m)
Nexium (oral) was included in China's VBP programme
implemented in February 2021 and Nexium i.v. was implemented in the fifth round of
VBP in October 2021
|
||
Others
|
|
273
|
(12%)
|
(10%)
|
|
||
|
|
|
|
|
|
|
|
|
|
YTD 2022
|
YTD 2021
|
% Change
|
Q3 2022
|
Q3 2021
|
% Change
|
|
||
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
|
33,144
|
25,406
|
30
|
37
|
10,982
|
9,866
|
11
|
19
|
|
- Product Sales
|
|
32,200
|
25,043
|
29
|
35
|
10,590
|
9,741
|
9
|
16
|
|
- Collaboration Revenue
|
|
944
|
363
|
>2x
|
>2x
|
392
|
125
|
>3x
|
>3x
|
|
Cost of Sales
|
|
(9,491)
|
(7,812)
|
21
|
28
|
(2,982)
|
(3,757)
|
(21)
|
(18)
|
|
Gross Profit
|
|
23,653
|
17,594
|
34
|
40
|
8,000
|
6,109
|
31
|
41
|
|
Gross Margin
|
|
70.5%
|
68.8%
|
+2pp
|
+2pp
|
71.8%
|
61.4%
|
+10pp
|
+11pp
|
|
Distribution Expense
|
|
(380)
|
(322)
|
18
|
25
|
(126)
|
(120)
|
5
|
13
|
|
% Total Revenue
|
|
1.1%
|
1.3%
|
-
|
-
|
1.1%
|
1.2%
|
-
|
-
|
|
R&D Expense
|
|
(7,137)
|
(7,152)
|
-
|
4
|
(2,458)
|
(3,610)
|
(32)
|
(28)
|
|
% Total Revenue
|
|
21.5%
|
28.2%
|
+7pp
|
+7pp
|
22.4%
|
36.6%
|
+14pp
|
+14pp
|
|
SG&A Expense
|
|
(13,798)
|
(10,117)
|
36
|
41
|
(4,277)
|
(4,090)
|
5
|
9
|
|
% Total Revenue
|
|
41.6%
|
39.8%
|
-2pp
|
-1pp
|
38.9%
|
41.5%
|
+3pp
|
+3pp
|
|
OOI[62] &
Expense
|
|
325
|
1,345
|
(76)
|
(75)
|
106
|
37
|
>2x
|
>2x
|
|
% Total Revenue
|
|
1.0%
|
5.3%
|
-4pp
|
-4pp
|
1.0%
|
0.4%
|
+1pp
|
+1pp
|
|
Operating Profit/(Loss)
|
|
2,663
|
1,348
|
98
|
>2x
|
1,245
|
(1,674)
|
n/m
|
n/m
|
|
Operating Margin
|
|
8.0%
|
5.3%
|
+3pp
|
+3pp
|
11.3%
|
-17.0%
|
+28pp
|
+30pp
|
|
Net Finance Expense
|
|
(936)
|
(922)
|
1
|
6
|
(324)
|
(320)
|
1
|
2
|
|
Joint Ventures and Associates
|
|
(4)
|
(55)
|
(93)
|
(91)
|
1
|
(7)
|
n/m
|
n/m
|
|
Profit/(Loss) before tax
|
|
1,723
|
371
|
>4x
|
>4x
|
922
|
(2,001)
|
n/m
|
n/m
|
|
Taxation
|
|
668
|
90
|
>7x
|
>7x
|
720
|
350
|
>2x
|
>2x
|
|
Tax rate
|
|
-39%
|
-24%
|
|
|
-78%
|
-18%
|
|
|
|
Profit/(Loss) after tax
|
|
2,391
|
461
|
>5x
|
>5x
|
1,642
|
(1,651)
|
n/m
|
n/m
|
|
Earnings per share
|
|
$1.54
|
$0.33
|
>4x
|
>4x
|
$1.06
|
$(1.10)
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD 2022
|
YTD 2021
|
% Change
|
Q3 2022
|
Q3 2021
|
% Change
|
||
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
Reported Profit/(Loss) before tax
|
|
1,723
|
371
|
>4x
|
>4x
|
922
|
(2,001)
|
n/m
|
n/m
|
Net Finance Expense
|
|
936
|
922
|
1
|
6
|
324
|
320
|
1
|
2
|
Joint Ventures and Associates
|
|
4
|
55
|
(93)
|
(91)
|
(1)
|
7
|
n/m
|
n/m
|
Depreciation, Amortisation and Impairment
|
|
4,000
|
4,338
|
(8)
|
(4)
|
1,334
|
2,788
|
(52)
|
(49)
|
EBITDA
|
|
6,663
|
5,686
|
17
|
26
|
2,579
|
1,114
|
>2x
|
>2x
|
YTD 2022
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisitionof Alexion
|
Other
|
Core
|
Core
% Change
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
Gross Profit
|
|
23,653
|
156
|
24
|
3,186
|
(1)
|
27,018
|
43
|
48
|
Gross Margin
|
|
70.5%
|
|
|
|
|
81.0%
|
+7pp
|
+6pp
|
Distribution Expense
|
|
(380)
|
2
|
-
|
-
|
-
|
(378)
|
17
|
24
|
R&D Expense
|
|
(7,137)
|
57
|
83
|
23
|
-
|
(6,974)
|
25
|
29
|
SG&A Expense
|
|
(13,798)
|
263
|
3,060
|
35
|
1,197[63]
|
(9,243)
|
20
|
24
|
Total Operating Expense
|
|
(21,315)
|
322
|
3,143
|
58
|
1,197
|
(16,595)
|
22
|
26
|
Other Operating Income & Expense
|
|
325
|
(8)
|
-
|
-
|
-
|
317
|
(76)
|
(76)
|
Operating Profit
|
|
2,663
|
470
|
3,167
|
3,244
|
1,196
|
10,740
|
63
|
69
|
Operating Margin
|
|
8.0%
|
|
|
|
|
32.4%
|
+6pp
|
+6pp
|
Net Finance Expense
|
|
(936)
|
-
|
-
|
|
207
|
(729)
|
16
|
21
|
Taxation
|
|
668
|
(93)
|
(581)
|
(748)
|
(1,078)[64]
|
(1,832)
|
84
|
90
|
EPS
|
|
$1.54
|
$0.25
|
$1.67
|
$1.61
|
$0.21
|
$5.28
|
47
|
52
|
Q3 2022
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisitionof Alexion
|
Other
|
Core
|
Core
% Change
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
Gross Profit
|
|
8,000
|
75
|
8
|
866
|
(1)
|
8,948
|
21
|
30
|
Gross Margin
|
|
71.8%
|
|
|
|
|
80.8%
|
+6pp
|
+7pp
|
Distribution Expense
|
|
(126)
|
1
|
-
|
-
|
-
|
(125)
|
5
|
12
|
R&D Expense
|
|
(2,458)
|
19
|
77
|
5
|
-
|
(2,357)
|
10
|
16
|
SG&A Expense
|
|
(4,277)
|
65
|
979
|
5
|
68
|
(3,160)
|
10
|
16
|
Total Operating Expense
|
|
(6,861)
|
85
|
1,056
|
10
|
68
|
(5,642)
|
10
|
16
|
Other Operating Income & Expense
|
|
106
|
1
|
-
|
-
|
-
|
107
|
>2x
|
>3x
|
Operating Profit
|
|
1,245
|
161
|
1,064
|
876
|
67
|
3,413
|
50
|
63
|
Operating Margin
|
|
11.3%
|
|
|
|
|
31.1%
|
+8pp
|
+9pp
|
Net Finance Expense
|
|
(324)
|
-
|
-
|
-
|
70
|
(254)
|
16
|
14
|
Taxation
|
|
720
|
(32)
|
(194)
|
(202)
|
(871)
|
(579)
|
31
|
43
|
EPS
|
|
$1.06
|
$0.08
|
$0.56
|
$0.44
|
($0.47)
|
$1.67
|
55
|
70
|
|
|
YTD 2022
|
YTD 2021
|
Change
|
|
|
$m
|
$m
|
$m
|
Reported Operating Profit
|
|
2,663
|
1,348
|
1,315
|
Depreciation, Amortisation and Impairment
|
|
4,000
|
4,338
|
(338)
|
Decrease in Working Capital and Short-term Provisions
|
|
3,458
|
2,063
|
1,395
|
Gains on Disposal of Intangible Assets
|
|
(88)
|
(371)
|
283
|
Gains on Disposal of Investments in Associates and Joint
Ventures
|
|
-
|
(776)
|
776
|
Fair value movements on contingent consideration arising from
business combinations
|
|
293
|
33
|
260
|
Non-Cash and Other Movements
|
|
(973)
|
(370)
|
(603)
|
Interest Paid
|
|
(608)
|
(522)
|
(86)
|
Taxation Paid
|
|
(1,335)
|
(1,198)
|
(137)
|
Net Cash Inflow from Operating Activities
|
|
7,410
|
4,545
|
2,865
|
Net Cash Inflow/(Outflow) before Financing Activities
|
|
4,699
|
(5,600)
|
10,299
|
Net Cash (Outflow)/Inflow from Financing Activities
|
|
(6,465)
|
4,700
|
(11,165)
|
|
|
At 30
Sep 2022
|
At 31
Dec 2021
|
At 30
Sep 2021
|
|
|
$m
|
$m
|
$m
|
Cash and cash equivalents
|
|
4,458
|
6,329
|
7,067
|
Other investments
|
|
440
|
69
|
82
|
Cash and investments
|
|
4,898
|
6,398
|
7,149
|
Overdrafts and short-term borrowings
|
|
(743)
|
(387)
|
(605)
|
Lease liabilities
|
|
(878)
|
(987)
|
(962)
|
Current instalments of loans
|
|
(4,665)
|
(1,273)
|
(2,139)
|
Non-current instalments of loans
|
|
(23,013)
|
(28,134)
|
(28,206)
|
Interest-bearing loans and borrowings (Gross Debt)
|
|
(29,299)
|
(30,781)
|
(31,912)
|
Net derivatives
|
|
(141)
|
61
|
90
|
Net Debt
|
|
(24,542)
|
(24,322)
|
(24,673)
|
|
|
YTD 2022
|
YTD 2021
|
|
|
$m
|
$m
|
Total Revenue
|
|
-
|
-
|
Gross Profit
|
|
-
|
-
|
Operating loss
|
|
(3)
|
(131)
|
Loss for the period
|
|
(404)
|
(553)
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
502
|
5,731
|
|
|
At 30 Sep 2022
|
At 30 Sep 2021
|
|
|
$m
|
$m
|
Current assets
|
|
5
|
12
|
Non-current assets
|
|
-
|
-
|
Current liabilities
|
|
(3,067)
|
(2,347)
|
Non-current liabilities
|
|
(22,556)
|
(25,721)
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
7,349
|
12,137
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
(301)
|
(299)
|
|
|
|
Average spot
rates vs USD
|
|
Spot rate vs USD
|
|
Annual impact of 5%
strengthening inFY average rate vs USD
($m) [66]
|
Currency
|
Primary Relevance
|
|
FY 2021[67]
|
YTD 2022[68]
|
Change
(%)
|
|
31 Oct 2022
|
Change[69]
(%)
|
|
Total Revenue
|
Core Operating Profit
|
CNY
|
Total Revenue
|
|
6.43
|
6.62
|
(3)
|
|
7.31
|
(12)
|
|
277
|
158
|
EUR
|
Total Revenue
|
|
0.85
|
0.94
|
(10)
|
|
1.01
|
(16)
|
|
317
|
160
|
JPY
|
Total Revenue
|
|
109.83
|
128.34
|
(14)
|
|
148.02
|
(26)
|
|
229
|
158
|
Other[70]
|
|
|
|
|
|
|
|
|
|
420
|
196
|
GBP
|
Operating Expense
|
|
0.73
|
0.80
|
(9)
|
|
0.86
|
(16)
|
|
61
|
(93)
|
SEK
|
Operating Expense
|
|
8.58
|
9.92
|
(13)
|
|
10.98
|
(22)
|
|
6
|
(82)
|
For the nine months ended 30 September
|
|
2022
|
2021
|
|
|
$m
|
$m
|
Total Revenue
|
|
33,144
|
25,406
|
Product Sales
|
|
32,200
|
25,043
|
Collaboration Revenue
|
|
944
|
363
|
Cost of Sales
|
|
(9,491)
|
(7,812)
|
Gross profit
|
|
23,653
|
17,594
|
Distribution expense
|
|
(380)
|
(322)
|
Research and development expense
|
|
(7,137)
|
(7,152)
|
Selling, general and administrative expense
|
|
(13,798)
|
(10,117)
|
Other operating income and expense
|
|
325
|
1,345
|
Operating profit
|
|
2,663
|
1,348
|
Finance income
|
|
50
|
42
|
Finance expense
|
|
(986)
|
(964)
|
Share of after tax losses in associates and joint
ventures
|
|
(4)
|
(55)
|
Profit before tax
|
|
1,723
|
371
|
Taxation
|
|
668
|
90
|
Profit for the period
|
|
2,391
|
461
|
Other comprehensive (loss)/income
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
1,283
|
592
|
Net (losses)/gains on equity investments measured at fair value
through other comprehensive income
|
|
(21)
|
144
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
1
|
4
|
Tax on items that will not be reclassified to profit or
loss
|
|
(291)
|
71
|
|
|
972
|
811
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
Foreign exchange arising on consolidation
|
|
(2,493)
|
(368)
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
|
(321)
|
(275)
|
Fair value movements on cash flow hedges
|
|
(214)
|
(103)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
|
250
|
137
|
Fair value movements on derivatives designated in net investment
hedges
|
|
33
|
22
|
Costs of hedging
|
|
(11)
|
(6)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
95
|
37
|
|
|
(2,661)
|
(556)
|
Other comprehensive (loss)/income, net of tax
|
|
(1,689)
|
255
|
Total comprehensive income for the period
|
|
702
|
716
|
Profit attributable to:
|
|
|
|
Owners of the Parent
|
|
2,387
|
459
|
Non-controlling interests
|
|
4
|
2
|
|
|
2,391
|
461
|
Total comprehensive income attributable to:
|
|
|
|
Owners of the Parent
|
|
701
|
714
|
Non-controlling interests
|
|
1
|
2
|
|
|
702
|
716
|
Basic earnings per $0.25 Ordinary Share
|
|
$1.54
|
$0.33
|
Diluted earnings per $0.25 Ordinary Share
|
|
$1.53
|
$0.33
|
Weighted average number of Ordinary Shares in issue
(m)
|
|
1,548
|
1,374
|
Diluted weighted average number of Ordinary Shares in issue
(m)
|
|
1,560
|
1,382
|
For the quarter ended 30 September
|
|
2022
|
2021
|
|
|
$m
|
$m
|
Total Revenue
|
|
10,982
|
9,866
|
Product Sales
|
|
10,590
|
9,741
|
Collaboration Revenue
|
|
392
|
125
|
Cost of Sales
|
|
(2,982)
|
(3,757)
|
Gross profit
|
|
8,000
|
6,109
|
Distribution expense
|
|
(126)
|
(120)
|
Research and development expense
|
|
(2,458)
|
(3,610)
|
Selling, general and administrative expense
|
|
(4,277)
|
(4,090)
|
Other operating income and expense
|
|
106
|
37
|
Operating profit/(loss)
|
|
1,245
|
(1,674)
|
Finance income
|
|
15
|
15
|
Finance expense
|
|
(339)
|
(335)
|
Share of after tax profits/(losses) in associates and joint
ventures
|
|
1
|
(7)
|
Profit/(Loss) before tax
|
|
922
|
(2,001)
|
Taxation
|
|
720
|
350
|
Profit/(Loss) for the period
|
|
1,642
|
(1,651)
|
Other comprehensive loss
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
252
|
(100)
|
Net (losses)/gains on equity investments measured at fair value
through other comprehensive income
|
|
(9)
|
171
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
(1)
|
2
|
Tax on items that will not be reclassified to profit or
loss
|
|
(16)
|
19
|
|
|
226
|
92
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
Foreign exchange arising on consolidation
|
|
(1,167)
|
(427)
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
|
(126)
|
(45)
|
Fair value movements on cash flow hedges
|
|
(76)
|
(44)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
|
119
|
64
|
Fair value movements on derivatives designated in net investment
hedges
|
|
(1)
|
15
|
Costs of hedging
|
|
2
|
(4)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
49
|
19
|
|
|
(1,200)
|
(422)
|
Other comprehensive loss, net of tax
|
|
(974)
|
(330)
|
Total comprehensive income/(loss) for the period
|
|
668
|
(1,981)
|
Profit/(Loss) attributable to:
|
|
|
|
Owners of the Parent
|
|
1,640
|
(1,652)
|
Non-controlling interests
|
|
2
|
1
|
|
|
1,642
|
(1,651)
|
Total comprehensive income/(loss) attributable to:
|
|
|
|
Owners of the Parent
|
|
667
|
(1,982)
|
Non-controlling interests
|
|
1
|
1
|
|
|
668
|
(1,981)
|
Basic earnings per $0.25 Ordinary Share
|
|
$1.06
|
$(1.10)
|
Diluted earnings per $0.25 Ordinary Share
|
|
$1.05
|
$(1.10)
|
Weighted average number of Ordinary Shares in issue
(m)
|
|
1,548
|
1,496
|
Diluted weighted average number of Ordinary Shares in issue
(m)
|
|
1,559
|
1,496
|
|
|
At 30 Sep 2022
|
At 31 Dec 2021
|
At 30 Sep 2021
|
|
|
$m
|
$m
|
$m
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property, plant and equipment
|
|
8,352
|
9,183
|
9,214
|
Right-of-use assets
|
|
875
|
988
|
948
|
Goodwill
|
|
19,707
|
19,997
|
20,081
|
Intangible assets
|
|
39,585
|
42,387
|
44,104
|
Investments in associates and joint ventures
|
|
53
|
69
|
39
|
Other investments
|
|
1,049
|
1,168
|
1,546
|
Derivative financial instruments
|
|
112
|
102
|
90
|
Other receivables
|
|
792
|
895
|
811
|
Deferred tax assets
|
|
3,436
|
4,330
|
3,697
|
|
|
73,961
|
79,119
|
80,530
|
Current assets
|
|
|
|
|
Inventories
|
|
5,078
|
8,983
|
10,528
|
Trade and other receivables
|
|
9,336
|
9,644
|
8,258
|
Other investments
|
|
440
|
69
|
82
|
Derivative financial instruments
|
|
105
|
83
|
60
|
Intangible assets
|
|
82
|
105
|
100
|
Income tax receivable
|
|
725
|
663
|
596
|
Cash and cash equivalents
|
|
4,458
|
6,329
|
7,067
|
Assets held for sale
|
|
-
|
368
|
-
|
|
|
20,224
|
26,244
|
26,691
|
Total assets
|
|
94,185
|
105,363
|
107,221
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(5,408)
|
(1,660)
|
(2,744)
|
Lease liabilities
|
|
(210)
|
(233)
|
(229)
|
Trade and other payables
|
|
(17,694)
|
(18,938)
|
(18,663)
|
Derivative financial instruments
|
|
(68)
|
(79)
|
(54)
|
Provisions
|
|
(377)
|
(768)
|
(972)
|
Income tax payable
|
|
(1,093)
|
(916)
|
(987)
|
|
|
(24,850)
|
(22,594)
|
(23,649)
|
Non-current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(23,013)
|
(28,134)
|
(28,206)
|
Lease liabilities
|
|
(668)
|
(754)
|
(733)
|
Derivative financial instruments
|
|
(290)
|
(45)
|
(6)
|
Deferred tax liabilities
|
|
(3,479)
|
(6,206)
|
(6,400)
|
Retirement benefit obligations
|
|
(919)
|
(2,454)
|
(2,449)
|
Provisions
|
|
(930)
|
(956)
|
(726)
|
Other payables
|
|
(4,882)
|
(4,933)
|
(5,140)
|
|
|
(34,181)
|
(43,482)
|
(43,660)
|
Total liabilities
|
|
(59,031)
|
(66,076)
|
(67,309)
|
Net assets
|
|
35,154
|
39,287
|
39,912
|
Equity
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
Share capital
|
|
387
|
387
|
387
|
Share premium account
|
|
35,137
|
35,126
|
35,118
|
Other reserves
|
|
2,081
|
2,045
|
2,039
|
Retained earnings
|
|
(2,471)
|
1,710
|
2,200
|
|
|
35,134
|
39,268
|
39,744
|
Non-controlling interests
|
|
20
|
19
|
168
|
Total equity
|
|
35,154
|
39,287
|
39,912
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2021
|
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
Profit for the period
|
|
-
|
-
|
-
|
459
|
459
|
2
|
461
|
Other comprehensive income
|
|
-
|
-
|
-
|
255
|
255
|
-
|
255
|
Transfer to other reserves
|
|
-
|
-
|
15
|
(15)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,884)
|
(3,884)
|
-
|
(3,884)
|
Issue of Ordinary Shares
|
|
59
|
27,147
|
-
|
-
|
27,206
|
-
|
27,206
|
Changes in non-controlling interest
|
|
-
|
-
|
-
|
-
|
-
|
150
|
150
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
384
|
384
|
-
|
384
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(811)
|
(811)
|
-
|
(811)
|
Issue of replacement share awards upon acquisition
|
|
-
|
-
|
-
|
513
|
513
|
-
|
513
|
Net movement
|
|
59
|
27,147
|
15
|
(3,099)
|
24,122
|
152
|
24,274
|
At 30 Sep 2021
|
|
387
|
35,118
|
2,039
|
2,200
|
39,744
|
168
|
39,912
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2022
|
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
Profit for the period
|
|
-
|
-
|
-
|
2,387
|
2,387
|
4
|
2,391
|
Other comprehensive loss
|
|
-
|
-
|
-
|
(1,686)
|
(1,686)
|
(3)
|
(1,689)
|
Transfer to other reserves
|
|
-
|
-
|
36
|
(36)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(4,486)
|
(4,486)
|
-
|
(4,486)
|
Issue of Ordinary Shares
|
|
-
|
11
|
-
|
-
|
11
|
-
|
11
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
471
|
471
|
-
|
471
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(831)
|
(831)
|
-
|
(831)
|
Net movement
|
|
-
|
11
|
36
|
(4,181)
|
(4,134)
|
1
|
(4,133)
|
At 30 Sep 2022
|
|
387
|
35,137
|
2,081
|
(2,471)
|
35,134
|
20
|
35,154
|
For the nine months ended 30 September
|
|
2022
|
2021
|
|
$m
|
$m
|
Cash flows from operating activities
|
|
|
|
Profit before tax
|
|
1,723
|
371
|
Finance income and expense
|
|
936
|
922
|
Share of after tax losses of associates and joint
ventures
|
|
4
|
55
|
Depreciation, amortisation and impairment
|
|
4,000
|
4,338
|
Decrease in working capital and short-term provisions
|
|
3,458
|
2,063
|
Gains on disposal of intangible assets
|
|
(88)
|
(371)
|
Gains on disposal of investments in associates and joint
ventures
|
|
-
|
(776)
|
Fair value movements on contingent consideration arising from
business combinations
|
|
293
|
33
|
Non-cash
and other movements
|
|
(973)
|
(370)
|
Cash generated from operations
|
|
9,353
|
6,265
|
Interest paid
|
|
(608)
|
(522)
|
Tax paid
|
|
(1,335)
|
(1,198)
|
Net cash inflow from operating activities
|
|
7,410
|
4,545
|
Cash flows from investing activities
|
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
|
-
|
(9,263)
|
Payments upon vesting of employee share awards attributable to
business combinations
|
|
(297)
|
(203)
|
Payment of contingent consideration from business
combinations
|
|
(570)
|
(470)
|
Purchase of property, plant and equipment
|
|
(719)
|
(768)
|
Disposal of property, plant and equipment
|
|
17
|
10
|
Purchase of intangible assets
|
|
(1,298)
|
(714)
|
Disposal of intangible assets and assets held for sale
|
|
442
|
584
|
Purchase of non-current asset investments
|
|
(28)
|
(190)
|
Disposal of non-current asset investments
|
|
42
|
-
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
|
(321)
|
120
|
Payments to associates and joint ventures
|
|
(5)
|
(55)
|
Disposal of investments in associates and joint
ventures
|
|
-
|
776
|
Interest received
|
|
26
|
28
|
Net cash outflow from investing activities
|
|
(2,711)
|
(10,145)
|
Net cash inflow/(outflow) before financing activities
|
|
4,699
|
(5,600)
|
Cash flows from financing activities
|
|
|
|
Proceeds from issue of share capital
|
|
11
|
10
|
Repayment of loans and borrowings
|
|
(1,261)
|
(2,934)
|
Issue of loans
|
|
-
|
11,942
|
Dividends paid
|
|
(4,364)
|
(3,856)
|
Hedge contracts relating to dividend payments
|
|
(127)
|
(28)
|
Repayment of obligations under leases
|
|
(182)
|
(173)
|
Movement in short-term borrowings
|
|
378
|
(261)
|
Payment of Acerta Pharma share purchase liability
|
|
(920)
|
-
|
Net cash (outflow)/inflow from financing activities
|
|
(6,465)
|
4,700
|
Net decrease in cash and cash equivalents in the
period
|
|
(1,766)
|
(900)
|
Cash and cash equivalents at the beginning of the
period
|
|
6,038
|
7,546
|
Exchange rate effects
|
|
(86)
|
(73)
|
Cash and cash equivalents at the end of the period
|
|
4,186
|
6,573
|
Cash and cash equivalents consist of:
|
|
|
|
Cash and cash equivalents
|
|
4,458
|
7,067
|
Overdrafts
|
|
(272)
|
(494)
|
|
|
4,186
|
6,573
|
|
|
At 1 Jan 2022
|
Cash flow
|
Non-cash& other
|
Exchange movements
|
At 30 Sep 2022
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Non-current instalments of loans
|
|
(28,134)
|
-
|
4,662
|
459
|
(23,013)
|
Non-current instalments of leases
|
|
(754)
|
-
|
28
|
58
|
(668)
|
Total long-term debt
|
|
(28,888)
|
-
|
4,690
|
517
|
(23,681)
|
Current instalments of loans
|
|
(1,273)
|
1,261
|
(4,653)
|
-
|
(4,665)
|
Current instalments of leases
|
|
(233)
|
186
|
(181)
|
18
|
(210)
|
Commercial paper
|
|
-
|
(249)
|
-
|
-
|
(249)
|
Bank collateral received
|
|
(93)
|
(66)
|
-
|
-
|
(159)
|
Other short-term borrowings excluding overdrafts
|
|
(3)
|
(63)
|
-
|
3
|
(63)
|
Overdrafts
|
|
(291)
|
(8)
|
-
|
27
|
(272)
|
Total current debt
|
|
(1,893)
|
1,061
|
(4,834)
|
48
|
(5,618)
|
Gross borrowings
|
|
(30,781)
|
1,061
|
(144)
|
565
|
(29,299)
|
Net derivative financial instruments
|
|
61
|
73
|
(275)
|
-
|
(141)
|
Net borrowings
|
|
(30,720)
|
1,134
|
(419)
|
565
|
(29,440)
|
Cash and cash equivalents
|
|
6,329
|
(1,758)
|
-
|
(113)
|
4,458
|
Other investments - current
|
|
69
|
375
|
-
|
(4)
|
440
|
Cash and investments
|
|
6,398
|
(1,383)
|
-
|
(117)
|
4,898
|
Net Debt
|
|
(24,322)
|
(249)
|
(419)
|
448
|
(24,542)
|
|
|
2022
|
2021[85]
|
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
$m
|
$m
|
$m
|
$m
|
At 1 January
|
|
2,544
|
321
|
2,865
|
3,323
|
Settlements
|
|
(561)
|
(9)
|
(570)
|
(470)
|
Disposals
|
|
-
|
(121)
|
(121)
|
-
|
Revaluations
|
|
320
|
(27)
|
293
|
60
|
Discount unwind
|
|
121
|
5
|
126
|
169
|
At 30 September
|
|
2,424
|
169
|
2,593
|
3,082
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
Oncology
|
10,885
|
14
|
20
|
2,723
|
12
|
15
|
4,695
|
24
|
2,037
|
12
|
24
|
1,430
|
(2)
|
11
|
Tagrisso
|
4,102
|
11
|
16
|
1,211
|
20
|
22
|
1,472
|
14
|
777
|
7
|
19
|
642
|
(4)
|
10
|
Imfinzi
|
2,031
|
14
|
19
|
224
|
6
|
9
|
1,102
|
20
|
402
|
16
|
29
|
303
|
-
|
14
|
Lynparza
|
1,949
|
13
|
19
|
358
|
27
|
30
|
896
|
13
|
493
|
8
|
20
|
202
|
8
|
22
|
Calquence
|
1,469
|
74
|
77
|
28
|
n/m
|
n/m
|
1,192
|
58
|
200
|
n/m
|
n/m
|
49
|
n/m
|
n/m
|
Enhertu
|
52
|
n/m
|
n/m
|
34
|
n/m
|
n/m
|
-
|
-
|
14
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
Orpathys
|
34
|
n/m
|
n/m
|
34
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex
|
717
|
-
|
6
|
507
|
9
|
13
|
11
|
2
|
100
|
(11)
|
(2)
|
99
|
(23)
|
(12)
|
Faslodex
|
259
|
(21)
|
(14)
|
121
|
(1)
|
5
|
15
|
(37)
|
44
|
(53)
|
(48)
|
79
|
(12)
|
2
|
Iressa
|
90
|
(39)
|
(37)
|
75
|
(39)
|
(37)
|
6
|
(33)
|
2
|
(53)
|
(48)
|
7
|
(41)
|
(33)
|
Arimidex
|
85
|
(20)
|
(16)
|
66
|
(19)
|
(16)
|
-
|
25
|
1
|
(79)
|
(85)
|
18
|
(19)
|
(7)
|
Casodex
|
63
|
(48)
|
(45)
|
44
|
(53)
|
(52)
|
-
|
(99)
|
-
|
(87)
|
(85)
|
19
|
(28)
|
(18)
|
Others
|
34
|
(9)
|
(1)
|
21
|
(2)
|
4
|
1
|
n/m
|
4
|
(3)
|
8
|
8
|
(34)
|
(25)
|
BioPharmaceuticals: CVRM*
|
6,907
|
13
|
18
|
3,181
|
9
|
14
|
1,783
|
9
|
1,413
|
25
|
39
|
530
|
18
|
32
|
Farxiga
|
3,204
|
49
|
58
|
1,224
|
40
|
46
|
748
|
48
|
955
|
64
|
82
|
277
|
49
|
65
|
Brilinta
|
1,013
|
(10)
|
(7)
|
222
|
(13)
|
(11)
|
538
|
(4)
|
215
|
(18)
|
(9)
|
38
|
(20)
|
(16)
|
Lokelma
|
208
|
71
|
80
|
15
|
n/m
|
n/m
|
122
|
50
|
21
|
n/m
|
n/m
|
50
|
74
|
n/m
|
Roxadustat
|
148
|
2
|
4
|
148
|
2
|
4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Andexxa*
|
111
|
7
|
14
|
-
|
-
|
-
|
62
|
(25)
|
29
|
43
|
55
|
20
|
n/m
|
n/m
|
Crestor
|
824
|
(2)
|
4
|
630
|
6
|
10
|
50
|
(15)
|
30
|
(31)
|
(24)
|
114
|
(17)
|
(7)
|
Seloken/Toprol-XL
|
705
|
(6)
|
(2)
|
689
|
(6)
|
(2)
|
-
|
n/m
|
9
|
6
|
8
|
7
|
(13)
|
(6)
|
Bydureon
|
207
|
(29)
|
(28)
|
2
|
-
|
2
|
177
|
(27)
|
28
|
(34)
|
(27)
|
-
|
(97)
|
(94)
|
Onglyza
|
205
|
(28)
|
(25)
|
98
|
(35)
|
(31)
|
60
|
(3)
|
30
|
(37)
|
(30)
|
17
|
(31)
|
(29)
|
Others
|
282
|
(9)
|
(7)
|
153
|
1
|
4
|
26
|
(32)
|
96
|
(13)
|
(11)
|
7
|
(37)
|
(30)
|
BioPharmaceuticals: R&I
|
4,318
|
(3)
|
-
|
1,102
|
(16)
|
(14)
|
1,963
|
12
|
795
|
(13)
|
(3)
|
458
|
(3)
|
5
|
Symbicort
|
1,919
|
(6)
|
(2)
|
476
|
4
|
8
|
718
|
(11)
|
445
|
(11)
|
(1)
|
280
|
(3)
|
3
|
Fasenra
|
1,015
|
13
|
17
|
30
|
99
|
95
|
649
|
17
|
229
|
9
|
21
|
107
|
(10)
|
-
|
Breztri
|
282
|
n/m
|
n/m
|
71
|
76
|
78
|
164
|
n/m
|
22
|
n/m
|
n/m
|
25
|
43
|
66
|
Saphnelo
|
69
|
n/m
|
n/m
|
-
|
-
|
-
|
66
|
n/m
|
1
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Pulmicort
|
479
|
(33)
|
(31)
|
339
|
(41)
|
(41)
|
53
|
1
|
50
|
1
|
12
|
37
|
8
|
16
|
Daliresp
|
161
|
(5)
|
(4)
|
2
|
(16)
|
(11)
|
151
|
(2)
|
7
|
(39)
|
(33)
|
1
|
(20)
|
(18)
|
Bevespi
|
43
|
11
|
13
|
4
|
32
|
35
|
31
|
10
|
7
|
5
|
16
|
1
|
17
|
37
|
Others
|
350
|
(21)
|
(20)
|
180
|
(14)
|
(13)
|
131
|
40
|
34
|
(74)
|
(71)
|
5
|
(52)
|
(47)
|
BioPharmaceuticals: V&I
|
3,607
|
51
|
59
|
995
|
(7)
|
(6)
|
942
|
n/m
|
693
|
(20)
|
(12)
|
977
|
n/m
|
n/m
|
Vaxzevria
|
1,713
|
(20)
|
(16)
|
684
|
(35)
|
(36)
|
79
|
n/m
|
325
|
(56)
|
(51)
|
625
|
82
|
96
|
Evusheld
|
1,451
|
n/m
|
n/m
|
167
|
n/m
|
n/m
|
850
|
n/m
|
199
|
n/m
|
n/m
|
235
|
n/m
|
n/m
|
Synagis
|
384
|
n/m
|
n/m
|
144
|
n/m
|
n/m
|
2
|
(91)
|
123
|
51
|
63
|
115
|
n/m
|
n/m
|
FluMist
|
59
|
(22)
|
(13)
|
-
|
(74)
|
(74)
|
11
|
(52)
|
46
|
(10)
|
3
|
2
|
n/m
|
n/m
|
Rare Disease*
|
5,236
|
4
|
10
|
315
|
(10)
|
8
|
3,175
|
7
|
1,079
|
(2)
|
10
|
667
|
11
|
26
|
Soliris*
|
2,918
|
(7)
|
(2)
|
218
|
(29)
|
(9)
|
1,688
|
(3)
|
627
|
(20)
|
(10)
|
385
|
20
|
34
|
Ultomiris*
|
1,371
|
27
|
35
|
34
|
n/m
|
n/m
|
771
|
23
|
347
|
55
|
74
|
219
|
-
|
18
|
Strensiq*
|
687
|
13
|
15
|
25
|
35
|
25
|
546
|
16
|
59
|
(4)
|
8
|
57
|
-
|
16
|
Koselugo
|
149
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
114
|
57
|
13
|
n/m
|
n/m
|
-
|
-
|
-
|
Kanuma*
|
111
|
6
|
11
|
16
|
9
|
7
|
56
|
10
|
33
|
(1)
|
12
|
6
|
11
|
20
|
Other medicines
|
1,247
|
(4)
|
4
|
608
|
(18)
|
(14)
|
112
|
(17)
|
95
|
(29)
|
(25)
|
432
|
50
|
72
|
Nexium
|
986
|
(1)
|
8
|
437
|
(24)
|
(19)
|
94
|
(4)
|
37
|
(22)
|
(13)
|
418
|
51
|
73
|
Others
|
261
|
(12)
|
(10)
|
171
|
5
|
7
|
18
|
(52)
|
58
|
(33)
|
(31)
|
14
|
39
|
48
|
Total Product Sales
|
32,200
|
29
|
35
|
8,924
|
5
|
8
|
12,670
|
56
|
6,112
|
19
|
32
|
4,494
|
39
|
56
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
Oncology
|
3,797
|
15
|
22
|
931
|
15
|
21
|
1,716
|
27
|
696
|
9
|
25
|
454
|
(9)
|
9
|
Tagrisso
|
1,398
|
12
|
20
|
406
|
29
|
35
|
521
|
18
|
268
|
4
|
19
|
203
|
(12)
|
5
|
Imfinzi
|
737
|
19
|
26
|
90
|
15
|
19
|
413
|
30
|
135
|
12
|
29
|
99
|
(1)
|
18
|
Lynparza
|
659
|
12
|
19
|
117
|
22
|
26
|
314
|
16
|
164
|
6
|
22
|
64
|
(5)
|
12
|
Calquence
|
566
|
60
|
63
|
12
|
n/m
|
n/m
|
457
|
48
|
79
|
n/m
|
n/m
|
18
|
n/m
|
n/m
|
Enhertu
|
23
|
n/m
|
n/m
|
15
|
n/m
|
n/m
|
-
|
-
|
6
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Orpathys
|
11
|
11
|
16
|
11
|
11
|
16
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex
|
240
|
(4)
|
5
|
176
|
4
|
11
|
4
|
43
|
31
|
(17)
|
(5)
|
29
|
(28)
|
(13)
|
Faslodex
|
81
|
(21)
|
(10)
|
40
|
(4)
|
5
|
5
|
(39)
|
12
|
(49)
|
(41)
|
24
|
(19)
|
-
|
Iressa
|
27
|
(35)
|
(31)
|
22
|
(33)
|
(29)
|
2
|
(47)
|
1
|
(49)
|
(56)
|
2
|
(30)
|
(19)
|
Arimidex
|
24
|
(28)
|
(23)
|
18
|
(25)
|
(21)
|
-
|
n/m
|
-
|
(93)
|
n/m
|
6
|
(29)
|
(17)
|
Casodex
|
21
|
(46)
|
(40)
|
17
|
(40)
|
(37)
|
-
|
n/m
|
(1)
|
n/m
|
n/m
|
5
|
(46)
|
(33)
|
Others
|
10
|
(18)
|
(10)
|
7
|
(13)
|
(6)
|
-
|
-
|
1
|
(20)
|
(8)
|
2
|
(38)
|
(25)
|
BioPharmaceuticals: CVRM*
|
2,348
|
11
|
19
|
1,081
|
9
|
16
|
632
|
9
|
469
|
20
|
37
|
166
|
11
|
30
|
Farxiga
|
1,101
|
38
|
50
|
410
|
28
|
38
|
279
|
38
|
329
|
55
|
78
|
83
|
35
|
57
|
Brilinta
|
338
|
(10)
|
(7)
|
76
|
(1)
|
-
|
187
|
(6)
|
65
|
(23)
|
(12)
|
10
|
(36)
|
(34)
|
Lokelma
|
79
|
59
|
69
|
9
|
n/m
|
n/m
|
45
|
37
|
8
|
n/m
|
n/m
|
17
|
31
|
59
|
Roxadustat
|
57
|
4
|
9
|
57
|
4
|
8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Andexxa*
|
41
|
5
|
17
|
-
|
-
|
-
|
20
|
(29)
|
11
|
2
|
17
|
10
|
n/m
|
n/m
|
Crestor
|
277
|
(7)
|
-
|
216
|
(4)
|
2
|
15
|
(16)
|
9
|
(17)
|
(4)
|
37
|
(16)
|
-
|
Seloken/Toprol-XL
|
238
|
2
|
10
|
233
|
2
|
10
|
-
|
n/m
|
3
|
9
|
22
|
2
|
(18)
|
(18)
|
Bydureon
|
66
|
(30)
|
(29)
|
-
|
(4)
|
(1)
|
58
|
(28)
|
8
|
(40)
|
(31)
|
-
|
n/m
|
n/m
|
Onglyza
|
66
|
(21)
|
(17)
|
32
|
(24)
|
(19)
|
20
|
12
|
9
|
(45)
|
(37)
|
5
|
(34)
|
(32)
|
Others
|
85
|
(11)
|
(8)
|
48
|
9
|
15
|
8
|
(24)
|
27
|
(27)
|
(25)
|
2
|
(52)
|
(45)
|
BioPharmaceuticals: R&I
|
1,427
|
(4)
|
1
|
371
|
(12)
|
(8)
|
663
|
9
|
244
|
(17)
|
(5)
|
149
|
(6)
|
4
|
Symbicort
|
630
|
(7)
|
(1)
|
169
|
13
|
18
|
237
|
(13)
|
133
|
(14)
|
(2)
|
91
|
(6)
|
2
|
Fasenra
|
353
|
10
|
15
|
12
|
87
|
78
|
229
|
15
|
77
|
2
|
16
|
35
|
(15)
|
(2)
|
Breztri
|
103
|
n/m
|
n/m
|
28
|
n/m
|
n/m
|
58
|
n/m
|
8
|
n/m
|
n/m
|
9
|
38
|
68
|
Saphnelo
|
33
|
n/m
|
n/m
|
-
|
-
|
-
|
32
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
Pulmicort
|
145
|
(33)
|
(31)
|
103
|
(40)
|
(40)
|
16
|
(6)
|
14
|
(4)
|
9
|
12
|
-
|
10
|
Daliresp
|
52
|
(4)
|
(3)
|
1
|
74
|
87
|
49
|
(1)
|
2
|
(43)
|
(35)
|
-
|
(55)
|
(54)
|
Bevespi
|
14
|
6
|
8
|
2
|
12
|
22
|
10
|
11
|
2
|
(22)
|
(11)
|
-
|
95
|
25
|
Others
|
97
|
(36)
|
(33)
|
56
|
(25)
|
(21)
|
32
|
(5)
|
8
|
(81)
|
(77)
|
1
|
(55)
|
(44)
|
BioPharmaceuticals: V&I
|
873
|
(27)
|
(21)
|
134
|
(78)
|
(78)
|
305
|
670
|
182
|
(28)
|
(16)
|
252
|
(12)
|
2
|
Vaxzevria
|
173
|
(83)
|
(81)
|
24
|
(96)
|
(97)
|
-
|
-
|
62
|
(62)
|
(56)
|
87
|
(63)
|
(59)
|
Evusheld
|
537
|
n/m
|
n/m
|
73
|
n/m
|
n/m
|
294
|
n/m
|
57
|
n/m
|
n/m
|
113
|
n/m
|
n/m
|
Synagis
|
104
|
(15)
|
(1)
|
37
|
n/m
|
n/m
|
-
|
n/m
|
17
|
(55)
|
(48)
|
50
|
(4)
|
17
|
FluMist
|
59
|
(19)
|
(10)
|
-
|
n/m
|
n/m
|
11
|
(53)
|
46
|
(7)
|
6
|
2
|
n/m
|
n/m
|
Rare Disease*
|
1,741
|
4
|
11
|
110
|
36
|
61
|
1,084
|
7
|
345
|
(10)
|
6
|
202
|
(1)
|
18
|
Soliris*
|
901
|
(13)
|
(6)
|
84
|
32
|
69
|
523
|
(13)
|
190
|
(27)
|
(15)
|
104
|
(5)
|
10
|
Ultomiris*
|
518
|
37
|
47
|
4
|
(40)
|
(37)
|
315
|
49
|
122
|
40
|
63
|
77
|
7
|
32
|
Strensiq*
|
237
|
17
|
20
|
8
|
73
|
53
|
192
|
22
|
18
|
(10)
|
4
|
19
|
(8)
|
12
|
Koselugo
|
48
|
82
|
81
|
7
|
n/m
|
n/m
|
36
|
42
|
5
|
n/m
|
n/m
|
-
|
-
|
-
|
Kanuma*
|
37
|
1
|
5
|
7
|
15
|
(1)
|
18
|
7
|
10
|
(15)
|
-
|
2
|
2
|
21
|
Other medicines
|
404
|
17
|
30
|
213
|
5
|
12
|
37
|
(9)
|
28
|
(21)
|
(15)
|
126
|
93
|
n/m
|
Nexium
|
311
|
20
|
36
|
148
|
(5)
|
3
|
31
|
(3)
|
10
|
(7)
|
8
|
122
|
n/m
|
n/m
|
Others
|
93
|
9
|
13
|
65
|
37
|
44
|
6
|
(28)
|
18
|
(27)
|
(25)
|
4
|
(22)
|
(19)
|
Total Product Sales
|
10,590
|
9
|
16
|
2,840
|
(9)
|
(3)
|
4,437
|
30
|
1,964
|
3
|
18
|
1,349
|
2
|
20
|
|
|
YTD 2022
|
YTD 2021
|
|
|
$m
|
$m
|
Enhertu: alliance
revenue
|
|
332
|
134
|
Tezspire: alliance
revenue
|
|
42
|
-
|
Lynparza: regulatory
milestones
|
|
250
|
-
|
Tralokinumab: sales milestones
|
|
110
|
-
|
Vaxzevria: royalties
|
|
67
|
83
|
Other royalty income
|
|
54
|
54
|
Other Collaboration Revenue
|
|
89
|
92
|
Total
|
|
944
|
363
|
|
|
YTD 2022
|
YTD 2021
|
|
|
$m
|
$m
|
Brazikumab licence termination funding
|
|
104
|
77
|
Divestment of rights to Plendil
|
|
61
|
-
|
Divestment of Viela Bio, Inc. shareholding
|
|
-
|
776
|
Crestor (Europe ex-UK and
Spain)
|
|
-
|
309
|
Other
|
|
160
|
183
|
Total
|
|
325
|
1,345
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca PLC
|
|
By: /s/ Adrian Kemp
|
|
Name: Adrian Kemp
|
|
Title: Company Secretary
|